Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775450 · ClinicalTrials.gov registry record · Phase 2
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 807
- Enrollment target
NCT00775450: Completed Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00775450 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 807 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (507% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00775450, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 807 participants
- Enrollment target
Study Summary
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with one of three Fluzone formulations.
Primary Outcome
Solicited injection site reactions: Pain, Erythema (redness), Swelling, Induration, Ecchymosis, Pruritus. Solicited systemic reactions: Fever, (Temperature), Headache, Malaise, Myalgia, and Shivering.
Interventions
- BIOLOGICAL Influenza Virus Vaccine USP Trivalent Types A and B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 807 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00775450 record still lists
NCT00775450 is an interventional study that assigns participants to a tested intervention. The registered 807 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (507% higher).
The record links to 0 conditions, and to 1 intervention - of which Influenza Virus Vaccine USP Trivalent Types A and B is the first listed.
NCT00775450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00775450 about?
NCT00775450 is a clinical study titled "Influenza Vaccine Revaccination in Ambulatory Elderly Subjects". This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with o...
What is the current status of trial NCT00775450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 807 participants. The study started on 2008-10. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00775450?
The interventions under investigation include: Influenza Virus Vaccine USP Trivalent Types A and B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00775450?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00775450's enrollment target sits among peer trials
807 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia